Ellevest Inc. Purchases 6,800 Shares of Pfizer Inc. $PFE

Ellevest Inc. increased its stake in Pfizer Inc. (NYSE:PFE) by 18.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,542 shares of the biopharmaceutical company’s stock after purchasing an additional 6,800 shares during the period. Ellevest Inc.’s holdings in Pfizer were worth $1,055,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the stock. Crestwood Advisors Group LLC raised its position in Pfizer by 5.0% in the 2nd quarter. Crestwood Advisors Group LLC now owns 143,000 shares of the biopharmaceutical company’s stock worth $3,466,000 after purchasing an additional 6,851 shares during the last quarter. Cassaday & Co Wealth Management LLC raised its position in Pfizer by 3.6% in the 2nd quarter. Cassaday & Co Wealth Management LLC now owns 28,891 shares of the biopharmaceutical company’s stock worth $700,000 after purchasing an additional 1,009 shares during the last quarter. NewSquare Capital LLC raised its position in Pfizer by 4.4% in the 2nd quarter. NewSquare Capital LLC now owns 161,980 shares of the biopharmaceutical company’s stock worth $3,880,000 after purchasing an additional 6,832 shares during the last quarter. J. W. Coons Advisors LLC raised its position in Pfizer by 6.0% in the 2nd quarter. J. W. Coons Advisors LLC now owns 35,241 shares of the biopharmaceutical company’s stock worth $854,000 after purchasing an additional 1,996 shares during the last quarter. Finally, Prosperity Consulting Group LLC raised its position in Pfizer by 3.6% in the 2nd quarter. Prosperity Consulting Group LLC now owns 53,776 shares of the biopharmaceutical company’s stock worth $1,304,000 after purchasing an additional 1,893 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on PFE shares. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 target price on shares of Pfizer in a report on Friday. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $28.24.

Pfizer Price Performance

Shares of PFE stock opened at $24.32 on Wednesday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $28.00. The firm has a market capitalization of $138.24 billion, a price-to-earnings ratio of 12.93, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a fifty day moving average of $24.75 and a 200-day moving average of $24.33.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. Pfizer’s payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.